.jpg)
In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Nabriva (NASDAQ: NBRV), with a price target of $20. The company’s shares opened today at $6, close to its 52-week low of $4.39.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 21.9% and a 44.7% success rate. Arce covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Conatus Pharmaceuticals, and Aurinia Pharmaceuticals.
Currently, the analyst consensus on Nabriva is Strong Buy and the average price target is $14.67, representing a 144.5% upside.
In a report issued on May 8, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $16 price target.
See today’s analyst top recommended stocks >>
Based on Nabriva’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $22.26 million. In comparison, last year the company had a GAAP net loss of $15.22 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nabriva Therapeutics Plc is a clinical stage biopharmaceutical company, which engages in the research and development of novel antibiotics to treat serious infections. Its lead product candidate, lefamulin, is a pleuromutilin antibiotic available for systemic administration in humans.
